Nektar Therapeutics Revenue Charts (NASDAQ:NKTR)
$22.61 $0.51 (2.21%) NKTR stock closing price Jul 27, 2017 (Closing)
The latest 2017-Q1 Nektar Therapeutics revenue is 24.73M. Compare Nektar Therapeutics revenue chart with Avanir Pharma revenue, Wuxi Pharmatech revenue.
Nektar Therapeutics Revenue Chart
You can do annual as well as quarterly comparisons of Nektar Therapeutics net sales with its competitor companies like Avanir Pharma, Wuxi Pharmatech. Over the 5 year period Nektar Therapeutics revenue in 2015 was highest at 230.78M. In the latest quarter, NKTR revenue 2017-Q1 has changed from 37.45M to 24.73M implying a decrease of 33.97%.
Nektar Therapeutics Quarterly Revenue
* Past 5 years Range
|Max NKTR Revenue||$132.87M||Sep, 2014|
|Min NKTR Revenue||$18.41M||Sep, 2012|
Nektar Therapeutics Annual Revenue
* Past 5 years Range
|Max NKTR Revenue||$230.78M||Dec, 2015|
|Min NKTR Revenue||$81.19M||Dec, 2012|
Nektar Therapeutics Annual Revenue VS Peers
|Nektar Therapeutics Revenue||$165.43M||$230.78M||$200.7M||$148.92M||$81.19M|
|Avanir Pharma Revenue||----||----||$115.02M||$75.36M||$41.27M|
|Wuxi Pharmatech Revenue||----||----||$674.27M||$578.08M||$499.91M|
|Progenics Pharma Revenue||$69.42M||$8.67M||$44.37M||$7.86M||$14.04M|
|Roche Holdings Revenue||$53.44B||$52.45B||$54.57B||$52.48B||$50.63B|
Nektar Therapeutics Stock Articles
Nektar Therapeutics News
Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy
Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain
Revenue or net sales is the total amount of money that a company brings in through its various business activities before any costs or expenses are deducted. Revenue is also known as the topline or net sales or gross income. Revenue is for a specific period of time and appears as the "top line" in an income statement. By subtracting the costs or expenses from Nektar Therapeutics topline, we arrive at the bottom line for the company. Growing revenues over a period of time generally indicate that the company is in good health, however other factors need to be factored. Revenue can be calculated in two ways based on the type of accounting followed: accrual accounting or cashflow accounting. It is useful to compare Nektar Therapeutics revenue with peers Indivior topline, Sage Therapeutics topline, Pfizer topline; to see how the company is doing with respect to its peers.